Amplia Therapeutics Limited announced the appointment of Christopher Burns Ph.D. as Chief Executive Officer, and Managing Director starting Dec. 5th 2022. Dr. Burns is a founder of Amplia and has served as a non-executive member of the Board of Directors.

Dr. Burns has over 30 years' experience in drug discovery and development and has served in executive level positions, including as CEO. Dr. Burns' deep experience in cancer biology and kinase inhibitor development has contributed to advancement of multiple clinical candidates and he was the lead inventor of the drug momelotinib, a Janus kinase (JAK) inhibitor targeting myelofibrosis, which was recently acquired by GSK for USD 1.9 billion. Dr. Burns will succeed Dr. John Lambert, who has served as Chief Executive Officer and Managing Director of the Company since June 2019 and February 2020, respectively.

Dr. Lambert and Dr. Burns will work together over the coming months to ensure a seamless transition of operations.